MedTrace Logo

Real-world Study of Efficacy and Safety of Zonisamide in add-on Therapy for Patients With Focal Epilepsy

NCT06374966 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-04-19

No results posted yet for this study

Summary

Patients were first observed for a 4-week baseline period, which required no medication adjustments and a seizure frequency of greater than or equal to 2 times per 4-week . After the baseline observation period, if the patients met the criteria for enrolment and there were no contraindications, zonisamide was added as an additional therapeutic drug.Clinical data were collected before the initiation of treatment, at 1 month, 3 months and 6 months after taking zonisamide respectively, with regular review of blood tests and urinary ultrasound, and imaging and electrophysiological examinations according to the clinical needs of the patient's actual condition.

Conditions

  • Epilepsies, Partial

Interventions

DRUG

Zonisamide

This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication

Sponsors & Collaborators

  • Hangzhou Children's Hospital

    collaborator UNKNOWN

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    collaborator OTHER

  • Jinhua Second Hospital

    collaborator UNKNOWN

  • Ningbo Medical Center Lihuili Hospital

    collaborator OTHER_GOV

  • Ningbo Women & Children's Hospital

    collaborator OTHER

  • Yuyao People's Hospital

    collaborator OTHER

  • Huzhou Third People's Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Jiaxing University

    collaborator OTHER

  • Lishui Country People's Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Shuang Wang, doctorate · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06374966 on ClinicalTrials.gov